Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Bayer welcomes judge's call for new trial in $2 billion glyphosate case

Published 07/19/2019, 05:01 AM
Updated 07/19/2019, 05:01 AM
© Reuters. FILE PHOTO:  Historic facade of Bayer AG headquarters of German pharmaceutical and chemical maker in Leverkusen

By Douglas Busvine

FRANKFURT (Reuters) - Germany's Bayer AG (DE:BAYGN) welcomed on Friday a call by a U.S. judge to cut a $2 billion damages award to a Californian couple by a jury which found that its glyphosate-based weed killer had caused their cancer.

The company had in June asked Judge Winifred Y. Smith, of California's Alameda County Superior Court, to overrule the jury verdict that its Roundup weed killer caused Alva and Alberta Pilliod's non-Hodgkin's Lymphoma (NHL), arguing it was not supported by the evidence.

Judge Smith, in a 15-page opinion, said the punitive damages that make up most of the award should be reduced. A hearing was due to be held on Friday on reduced damages and if the parties fail to agree, the case would go to a retrial.

"The court's tentative order proposes changes in the damage awards, which would be a step in the right direction," Bayer said in a statement. "Bayer will wait for a final order on the post-trial motions before commenting in further detail."

Shares in Bayer were up 1.9% at 0714 GMT.

The Oakland jury on May 13 awarded more than $2 billion to the Pilliods, finding their NHL to have been caused by using Monsanto's Roundup weed killer on their property between 1975 and 2011.

Bayer acquired Monsanto (NYSE:MON) for $63 billion last year, with the ensuing blowup of Roundup litigation hammering its value and leaving the German company with a stock market capitalization less than it paid in the takeover.

The jury awarded $18 million in compensatory and $1 billion in punitive damages to Alva Pilliod, and $37 million in compensatory and $1 billion in punitive damages to his wife.

PUNITIVE VS COMPENSATORY

Judge Smith's ruling said that the compensatory damages awarded by the jury for past non-economic loss were "not supportable by the evidence".

She also questioned the basis for the jury's larger damages award, saying she was inclined to find that punitive damages should be two to four times combined economic and non-economic compensatory damages.

Even assuming that compensatory damages are upheld, applying Judge Smith's thinking would result in maximum punitive damages of $220 million, according to a Reuters calculation - a fraction of the original jury award.

A Bayer spokesman declined to speculate on whether, and by how much, the damages award could be reduced pending Friday's hearing.

In a separate case last week, a U.S. federal judge slashed a damages award Bayer owed a California man who blamed Roundup weed killer for his cancer, to $25 million from $80 million, while rejecting the company's bid for a new trial.

The German drugmaker and chemicals company had said in court filings that the massive verdict in the Pilliod case was based on "inflammatory, fabricated and irrelevant evidence" from the couple's lawyers.

Judge Smith, however, denied Bayer's motion alleging misconduct on the part of the plaintiffs' lawyers.

© Reuters. FILE PHOTO:  Historic facade of Bayer AG headquarters of German pharmaceutical and chemical maker in Leverkusen

Bayer faces Roundup cancer lawsuits from more than 13,400 plaintiffs across the United States. It denies the allegations, saying the weed killer and its active ingredient glyphosate is safe for human use.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.